RU2745912C2 - Ацетил-лейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции - Google Patents

Ацетил-лейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции Download PDF

Info

Publication number
RU2745912C2
RU2745912C2 RU2018140131A RU2018140131A RU2745912C2 RU 2745912 C2 RU2745912 C2 RU 2745912C2 RU 2018140131 A RU2018140131 A RU 2018140131A RU 2018140131 A RU2018140131 A RU 2018140131A RU 2745912 C2 RU2745912 C2 RU 2745912C2
Authority
RU
Russia
Prior art keywords
subject
leucine
acetyl
treatment
pharmaceutically acceptable
Prior art date
Application number
RU2018140131A
Other languages
English (en)
Russian (ru)
Other versions
RU2018140131A3 (enExample
RU2018140131A (ru
Inventor
Мэллори ФЭКТОР
Михаэль ШТРУП
Original Assignee
Интрабио Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интрабио Лтд filed Critical Интрабио Лтд
Publication of RU2018140131A3 publication Critical patent/RU2018140131A3/ru
Publication of RU2018140131A publication Critical patent/RU2018140131A/ru
Application granted granted Critical
Publication of RU2745912C2 publication Critical patent/RU2745912C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
RU2018140131A 2016-04-19 2017-04-19 Ацетил-лейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции RU2745912C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
GB1606834.8 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021107001A Division RU2837641C2 (ru) 2016-04-19 2021-03-17 Ацетиллейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции

Publications (3)

Publication Number Publication Date
RU2018140131A3 RU2018140131A3 (enExample) 2020-05-14
RU2018140131A RU2018140131A (ru) 2020-05-14
RU2745912C2 true RU2745912C2 (ru) 2021-04-02

Family

ID=58633040

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018140131A RU2745912C2 (ru) 2016-04-19 2017-04-19 Ацетил-лейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции

Country Status (26)

Country Link
US (4) US10905670B2 (enExample)
EP (2) EP3445351B1 (enExample)
JP (3) JP7387264B2 (enExample)
KR (4) KR102632670B1 (enExample)
CN (2) CN109069463B (enExample)
AU (2) AU2017252507B2 (enExample)
BR (1) BR112018071547A2 (enExample)
CA (2) CA3309723A1 (enExample)
DK (1) DK3445351T3 (enExample)
ES (1) ES2994242T3 (enExample)
FI (1) FI3445351T3 (enExample)
HR (1) HRP20241552T1 (enExample)
HU (1) HUE069219T2 (enExample)
IL (3) IL293266B2 (enExample)
LT (1) LT3445351T (enExample)
MD (1) MD3445351T2 (enExample)
MX (2) MX388461B (enExample)
PL (1) PL3445351T3 (enExample)
PT (1) PT3445351T (enExample)
RS (1) RS66142B1 (enExample)
RU (1) RU2745912C2 (enExample)
SG (2) SG10202106190RA (enExample)
SI (1) SI3445351T1 (enExample)
SM (1) SMT202400459T1 (enExample)
WO (1) WO2017182802A1 (enExample)
ZA (1) ZA201806849B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3445351T (pt) 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2019000033A1 (fr) 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
CN119097618A (zh) * 2019-03-02 2024-12-10 内在生物技术有限公司 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
MD3989962T2 (ro) * 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2025019570A1 (en) 2023-07-18 2025-01-23 Sytheon Ltd. Novel amino acid based salts, compositions and methods for treating skin and rejuvenating skin and extending longevity
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine
RU2012151575A (ru) * 2010-06-03 2014-07-20 Рауф РЕКИК Нейропротекторное и ретинопротекторное средство n-ацетил-dl-лейцин

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
AU2007352854A1 (en) * 2007-05-08 2008-11-13 Northern Innovations And Formulations Corp. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
WO2011025518A1 (en) * 2009-08-27 2011-03-03 Albert Einstein College Of Medicine Of Yeshiva University Cognitive function training to improve motor ability
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
PT3445351T (pt) * 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
EP3697406A1 (en) * 2017-10-18 2020-08-26 IntraBio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine
RU2012151575A (ru) * 2010-06-03 2014-07-20 Рауф РЕКИК Нейропротекторное и ретинопротекторное средство n-ацетил-dl-лейцин

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
KLAUS JAHN et al.: "Dizziness and Unstable Gait in Old Age - Etiology, Diagnosis and Treatment", DEUTSCHES ARZTEBLATT INTERNATIONAL FEB 2013, 05.06.2015, vol.112, no.23, pp.387-393. *
MICHAEL STRUPP et al.: "Effects of acetyl-dl-leucine in patients with cerebellar ataxia: a case series", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, 09.07.2013, vol.260, no.10, pp.2556-2561. *
SHINICHI IWASAKI et al.: "Dizziness and Imbalance in the Elderly: Age-related Decline in the Vestibular System", AGING AND DISEASE, 02.02.2015, vol.6, no.1, pp.38-47. *
TATIANA BREMOVA et al.: "Acetyl-DL-leucine in Niemann-Pick type C: A case series", NEUROLOGY, 20.10.2015, vol.85, no.16, pp.1368-1375. *
TIGHILET BRAHIM et al.: "Comparative analysis of pharmacological treatments with N-acetyl-dl-leucine (Tanganil) and its two isomers (N-acetyl-L-leucine and N-acetyl-D-leucine) on vestibular compensation: Behavioral investigation in the cat", EUROPEAN JOURNAL OF PHARMACOLOGY, 19.11.2015, vol.769, pp. 42-349. *
TIGHILET BRAHIM et al.: "Comparative analysis of pharmacological treatments with N-acetyl-dl-leucine (Tanganil) and its two isomers (N-acetyl-L-leucine and N-acetyl-D-leucine) on vestibular compensation: Behavioral investigation in the cat", EUROPEAN JOURNAL OF PHARMACOLOGY, 19.11.2015, vol.769, pp. 42-349. MICHAEL STRUPP et al.: "Effects of acetyl-dl-leucine in patients with cerebellar ataxia: a case series", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, 09.07.2013, vol.260, no.10, pp.2556-2561. TATIANA BREMOVA et al.: "Acetyl-DL-leucine in Niemann-Pick type C: A case series", NEUROLOGY, 20.10.2015, vol.85, no.16, pp.1368-1375. SHINICHI IWASAKI et al.: "Dizziness and Imbalance in the Elderly: Age-related Decline in the Vestibular System", AGING AND DISEASE, 02.02.2015, vol.6, no.1, pp.38-47. KLAUS JAHN et al.: "Dizziness and Unstable Gait in Old Age - Etiology, Diagnosis and Treatment", DEUTSCHES ARZTEBLATT INTERNATIONAL FEB 2013, 05.06.2015, vol.112, no.23, pp.387-393. АНТОНЕНК *
АНТОНЕНКО Л.М. ВТОРОЙ КОНГРЕСС "МЕЖДУНАРОДНАЯ АКАДЕМИЯ ГОЛОВОКРУЖЕНИЯ", Неврологический журнал, 2015, т.20, с.51-53. *

Also Published As

Publication number Publication date
PL3445351T3 (pl) 2025-01-07
RS66142B1 (sr) 2024-12-31
CA3021155A1 (en) 2017-10-26
DK3445351T3 (da) 2024-11-04
KR20180134398A (ko) 2018-12-18
US20190083438A1 (en) 2019-03-21
EP3445351A1 (en) 2019-02-27
JP2022024058A (ja) 2022-02-08
MX388461B (es) 2025-03-20
KR102632670B1 (ko) 2024-02-01
SI3445351T1 (sl) 2025-04-30
JP2024123087A (ja) 2024-09-10
SG11201809031XA (en) 2018-11-29
IL262379A (en) 2018-11-29
AU2022256077A1 (en) 2022-11-17
JP2019513814A (ja) 2019-05-30
FI3445351T3 (fi) 2024-11-18
EP4501406A2 (en) 2025-02-05
RU2021107001A (ru) 2021-04-12
ZA201806849B (en) 2019-07-31
JP7506046B2 (ja) 2024-06-25
SMT202400459T1 (it) 2025-01-14
KR102791288B1 (ko) 2025-04-03
CN118593463A (zh) 2024-09-06
NZ747307A (en) 2025-10-31
HRP20241552T1 (hr) 2025-01-17
IL310508A (en) 2024-03-01
LT3445351T (lt) 2024-11-25
US20230346732A1 (en) 2023-11-02
US11998518B2 (en) 2024-06-04
RU2018140131A3 (enExample) 2020-05-14
IL293266B1 (en) 2024-03-01
US20250332133A1 (en) 2025-10-30
US10905670B2 (en) 2021-02-02
EP3445351B1 (en) 2024-10-16
US12329733B2 (en) 2025-06-17
KR20220038814A (ko) 2022-03-29
AU2017252507B2 (en) 2022-07-21
MD3445351T2 (ro) 2024-12-31
CN109069463B (zh) 2024-07-23
KR102413754B1 (ko) 2022-06-27
IL262379B (en) 2022-07-01
WO2017182802A1 (en) 2017-10-26
MX2021014844A (es) 2022-01-18
SG10202106190RA (en) 2021-07-29
MX2018012739A (es) 2019-06-17
EP4501406A3 (en) 2025-03-26
BR112018071547A2 (pt) 2019-03-06
HUE069219T2 (hu) 2025-02-28
JP7387264B2 (ja) 2023-11-28
CN109069463A (zh) 2018-12-21
KR20220093386A (ko) 2022-07-05
ES2994242T3 (en) 2025-02-05
AU2017252507A1 (en) 2018-11-08
IL293266A (en) 2022-07-01
PT3445351T (pt) 2024-11-14
IL293266B2 (en) 2024-07-01
KR20240018683A (ko) 2024-02-13
CA3309723A1 (en) 2026-06-21
US20210106548A1 (en) 2021-04-15
RU2018140131A (ru) 2020-05-14

Similar Documents

Publication Publication Date Title
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
IL271046A (en) Compounds for treating huntington's disease
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
EP3802539C0 (en) NOVEL TETRAHYDRO-1H-PYRAZINO[2,1-A]ISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EA201891286A1 (ru) АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3641829A4 (en) INTERFERON PRODRUG FOR TREATMENT OF CANCER
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
EP3807270C0 (en) NOVEL HETEROCYCLYL HETEROARYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
EP3741861A4 (en) SYNNOTCH RECEPTOR REGULATED EXPRESSION OF IL12
EP4744733A2 (en) Biphenylsulfonamide compounds for the treatment of kidney diseases or disorders
EA201990400A1 (ru) Соединения и композиции и их применение
HUE058921T2 (hu) Bisz-kolin-tetratiomolibdát wilson-betegség kezelésére
CA3015494C (en) Novel compositions and therapeutic methods
EP3496662A4 (en) SILICONE PROTEIN FOR THE TREATMENT OF IGNITION
HUE059387T2 (hu) Parkinson-kór kezelése
EP3982819A4 (en) METHODS FOR EVALUATION AND TREATMENT OF ALZHEIMER'S DISEASE AND APPLICATIONS THEREOF
EA201990450A1 (ru) Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
EP3735209A4 (en) TREATMENT OF THE PROGRESSION OF MYOPOIA
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
PT3603621T (pt) Lipossomas para o tratamento de doenças oculares
PT3458045T (pt) Ebselen para uso no tratamento da doença de ménière
MA43051A (fr) Polythérapie pour le traitement d'une du vhc
EP3610879A4 (en) COMPOSITION OF TREATMENT AND / OR PREVENTION OF ALZHEIMER'S DISEASE
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
EP3623369C0 (en) NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES